echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Cancer Sci: Aletinib can effectively and safely treat relapsed or refractory ALK-positive lymphoma

    Cancer Sci: Aletinib can effectively and safely treat relapsed or refractory ALK-positive lymphoma

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Inhibition of asexual lymphoma kinase (ALK) is expected to be an effective therapy for ALK-positive malignancies.


    Lymphoma

    The study included patients with relapsed or refractory ALK-positive ALCL (6 years of age or older).


     

    A total of 10 patients were enrolled, with a median age of 19.


    In summary, aletinib shows good clinical activity and is well tolerated in ALK-positive ALCL patients who have progressed with standard chemotherapy.


     

    Original source:

     

    Reiji Fukano, Tetsuya Mori, et al.


    Alectinib for relapsed or refractory anaplastic lymphoma kinase -positive anaplastic large cell lymphoma: An open-label phase II trial

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.